Application of a High-Content Multiparameter Cytotoxicity Assay to Prioritize Compounds Based on Toxicity Potential in Humans

Prioritization of compounds based on human hepatotoxicity potential is currently a key unmet need in drug discovery, as it can become a major problem for several lead compounds in later stages of the drug discovery pipeline. The authors report the validation and implementation of a high-content multiparametric cytotoxicity assay based on simultaneous measurement of 8 key cell health indicators associated with nuclear morphology, plasma membrane integrity, mitochondrial function, and cell proliferation. Compounds are prioritized by (a) computing an in vitro safety margin using the minimum cytotoxic concentration (IC20) across all 8 indicators and cell-based efficacy data and (b) using the minimal cytotoxic concentration alone to take into account concentration of drug in tissues. Feasibility data using selected compounds, including quinolone antibiotics, thiazolidinediones, and statins, suggest the viability of this approach. To increase overall throughput of compound prioritization, the authors have identified the higher throughput, plate reader—based CyQUANT® assay that is similar to the high-content screening (HCS) assay in sensitivity of measuring inhibition of cell proliferation. It is expected that the phenotypic output from the multiparametric HCS assay in combination with other highly sensitive approaches, such as microarray-based expression analysis of toxic signatures, will contribute to a better understanding and predictivity of human hepatotoxicity potential. (Journal of Biomolecular Screening 2008: 527-537)

[1]  T. Willson,et al.  The PPARs: From Orphan Receptors to Drug Discovery , 2000 .

[2]  P. Bernardi,et al.  High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening , 2006, Archives of Toxicology.

[3]  K. Hornbuckle,et al.  Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999 , 2001 .

[4]  K. Karsch,et al.  Effects of cerivastatin on human arterial smooth muscle cell proliferation and migration in transfilter cocultures. , 2000, Journal of cardiovascular pharmacology.

[5]  Jeffrey B. Gross,et al.  Timing of New Black Box Warnings and Withdrawals for Prescription Medications , 2003 .

[6]  J. Sahi,et al.  Induction of Drug Metabolism Enzymes and MDR1 Using a Novel Human Hepatocyte Cell Line , 2004, Journal of Pharmacology and Experimental Therapeutics.

[7]  P. Carmichael,et al.  Evaluation of an automated in vitro micronucleus assay in CHO-K1 cells. , 2007, Mutation research.

[8]  J. Waring,et al.  Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin , 2005, Hepatology.

[9]  M. Boyd,et al.  Inhibition of mitochondrial complex I by haloperidol: the role of thiol oxidation , 1999, Neuropharmacology.

[10]  P Smith,et al.  Concordance of the toxicity of pharmaceuticals in humans and in animals. , 2000, Regulatory toxicology and pharmacology : RTP.

[11]  D. L. Taylor,et al.  High content screening applied to large-scale cell biology. , 2004, Trends in biotechnology.

[12]  J. Lazo,et al.  A scalable high-content cytotoxicity assay insensitive to changes in mitochondrial metabolic activity. , 2004, Oncology research.

[13]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[14]  Ernesto Callegari,et al.  A comprehensive listing of bioactivation pathways of organic functional groups. , 2005, Current drug metabolism.

[15]  L. Saravolatz,et al.  Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae. , 2001, The Journal of antimicrobial chemotherapy.

[16]  Dominic P. Williams,et al.  Toxicophores: investigations in drug safety. , 2006, Toxicology.

[17]  L. Babiss,et al.  Toxicogenomics in predictive toxicology in drug development. , 2004, Chemistry & biology.

[18]  J. Haskins,et al.  Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leukocytes , 2001, Archives of Toxicology.